Bioethics International's Good Pharma Scorecard Publication Selected as BMJ Open Editors' Pick for 2015
Study Is One of the Most Frequently Read Articles Published in the Last Year
NEW YORK, Feb. 11, 2016 /PRNewswire/ -- Bioethics International, a not-for-profit organization focused on the ethics and governance of how medicines are researched, developed, marketed and made accessible to patients around the world, today announced that the editors of BMJ Open had named the publication of the Good Pharma Scorecard an 'Editors' Pick' for 2015. The publication is also featured as one of BMJ Open's 'Most Popular Articles', which includes those published in the last year that are most frequently read.
"In December we surveyed our staff editors, who oversee and manage the peer review process, to tell us about their favourite articles from 2015," wrote Ed Sucksmith, assistant editor of BMJ Open, in a BMJ Open blog post. "In our second editors' pick, Jennifer Miller and colleagues examined the levels of clinical trial registration, reporting and publication rates for new drugs approved by the Food and Drug Administration (FDA) in 2012."
The study sought to evaluate clinical trial registration, reporting and publication rates for 15 new drugs approved by the FDA in 2012 by both legal requirements, as established by the 2007 U.S. Food and Drug Administration Amendments Act (FDAAA), and the ethical standard that all human subject research should be publicly accessible to contribute to generalizable knowledge. Wide variation in practices among drugs and their sponsors was observed.
"We appreciate BMJ Open's support of clinical trial transparency and commitment to making research publicly available. Clinical trial transparency is important for advancing patient and global public health," said Jennifer E. Miller, Ph.D., president of Bioethics International, assistant professor of medical ethics in the Department of Population Health at NYU Langone Medical Center. "Following the interest we've had in the Good Pharma Scorecard, we remain focused on releasing the next set of rankings later this year."
About the Good Pharma Scorecard
The Good Pharma Scorecard measures and ranks pharmaceutical companies and new medicines and vaccines on key ethics, human rights & population health performance indicators. We focus on the ethical issues that impact patients the most. Our first scorecard ranks companies and new drugs on their clinical trial transparency, according to both legal and ethics standards. To see scores and data, please visit: Transparency Index | Legal Compliance Index.
About Bioethics International
Bioethics International's (BEI) mission is to empower professionals and organizations in healthcare, life science and biotechnology to make responsible decisions – on issues that impact patients the most. Currently, we focus on the ethics and governance of how medicines are researched, developed, marketed and made accessible to patients around the world. For more information, please visit www.bioethicsinternational.org.
Media Contacts
Tony Russo, Ph.D., or Lena Evans
Russo Partners, LLC
212-845-4251
212-845-4262
[email protected]
[email protected]
SOURCE Bioethics International
Share this article